Developing a novel strategy to prevent local recurrence of malignant glioma using primary human glioblastoma xenografts

• Project/Area Number: 16K10759
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Neurosurgery
• Research Institution: Kumamoto University
• Principal Investigator: Takezaki Tatsuya 熊本大学, 病院, 助教 (50712402)
• Project Period (FY): 2016-04-01 – 2020-03-31
• Project Status: Completed (Fiscal Year 2019)
• Budget Amount: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: 悪性グリオーマ / テモゾロミド / 局所再発 / 初代培養株 / グリオーマ初代培養株 / ヒトグリオーマ初代培養株 / 皮下連続継代モデル / ドラッグデリバリー / フィブリン糊

Outline of Final Research Achievements

The purpose of this project is to develop a novel strategy for preventing local recurrence of malignant glioma, because it is usually difficult due to blood-brain barrier.
I investigated that local administration of high concentration of temozolomide with fibrin glue could prevent tumor growth of primary malignant glioma xenografts derived from human glioblastoma.

Academic Significance and Societal Importance of the Research Achievements

膠芽腫（悪性グリオーマ）患者の平均生存期間は摘出術と放射線化学療法を併用しても約１４ヶ月であるが、膠芽腫は腫瘍摘出腔周囲からの再発が圧倒的に多く、これは腫瘍境界部に治療抵抗性のグリオーマ幹細胞と膠芽腫ニッチが存在することを示唆する。局所再発を防ぐことができれば膠芽腫の治療成績の向上が期待でき、その学術的意義、社会的意義は非常に大きいと考えられる。